总的来说，这项研究通过成功治疗一例 CD20 阴性双表达淋巴瘤患者，证明了 Pola-B 方案在难治性 CD20 阴性 B 细胞淋巴瘤治疗中的有效性。 这一成果为临床医生治疗这类难治性淋巴瘤提供了新的治疗思路和选择，也为后续进一步研究泊洛妥珠单抗维汀的作用机制以及基因与药物敏感性的关系奠定了基础。

12月23日，罗氏制药官方公众号发布罗氏又一款CD20/CD3双特异性抗体中国获批的消息。当中披露，中国国家药品监督管理局（NMPA ...

Characterization of self-assembled monolayers (SAM) of peptide mimotopes of CD20 antigen and their binding with rituximab (R) using Quartz Crystal Microbalance (QCM) Piezo-Immunosensors: A novel ...

Impaired Ca++ mobilization in rituximab-resistant cells (RRCL) is associated with changes in the structure of CD20 antigen, down-regulation of Bax/Bak pro-apoptotic proteins and up-regulation of the ...

Structure of CD20The CD20 protein presents a unique arrangement, featuring four membrane-spanning domains. Notably, both the amino and carboxy termini of the protein are positioned within the ...

Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies. Blood , 2023; 142 (20): 1724 DOI: 10.1182/blood.2023020400 Cite This Page : ...